Literature DB >> 16292323

Neurochemical effects of olanzapine in first-hospitalization manic adolescents: a proton magnetic resonance spectroscopy study.

Melissa P DelBello1, Kim M Cecil, Caleb M Adler, John P Daniels, Stephen M Strakowski.   

Abstract

We used proton magnetic resonance spectroscopy (1H MRS) to compare the in vivo effects of olanzapine on prefrontal N-acetyl-aspartate (NAA) levels in treatment remitters and nonremitters. Secondary aims of this study were to identify neurochemical predictors of successful olanzapine treatment and other neurochemical effects of olanzapine. In all, 20 adolescents admitted for their first hospitalization for bipolar disorder, type I, manic or mixed and 10 demographically matched healthy subjects were recruited. Manic adolescents were treated with olanzapine monotherapy and scanned at three time points (N = 19). Medial and left and right lateral ventral prefrontal NAA, choline, creatine/phosphocreatine, myo-inositol, and glutamate/glutamine were measured at baseline, prior to receiving medication, and on days 7 and 28 of treatment. Healthy subjects did not receive medication but underwent 1H MRS scans at the same time points to assess for normal variability in metabolites over time. Although there was no overall increase in NAA in manic adolescents following 28 days of treatment with olanzapine, olanzapine remitters (N = 11, 58%) exhibited a greater increase in medial ventral prefrontal NAA compared with nonremitters (N = 8, 42%, p = 0.006). Specifically, from baseline to end point, NAA levels decreased in nonremitters (p = 0.03) and increased in remitters (p = 0.05). Manic adolescents treated with olanzapine had an increase from baseline to day 7 in medial (p = 0.002) and right lateral (p = 0.02) ventral prefrontal choline. Baseline medial ventral prefrontal choline was greater in olanzapine remitters than in nonremitters (p = 0.001). Successful treatment of mania with olanzapine may lead to increased ventral prefrontal neuronal viability and/or function as compared to unsuccessful treatment with olanzapine. Additionally, olanzapine-induced increases in choline may lead to alteration of abnormalities in cell membrane metabolism or second messenger pathways that are thought to be involved in the pathophysiology of bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16292323     DOI: 10.1038/sj.npp.1300950

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  28 in total

Review 1.  Effects of early intervention on the course of bipolar disorder: theories and realities.

Authors:  Mani N Pavuluri
Journal:  Curr Psychiatry Rep       Date:  2010-12       Impact factor: 5.285

2.  Combined diffusion tensor imaging and transverse relaxometry in early-onset bipolar disorder.

Authors:  Atilla Gönenç; Jean A Frazier; David J Crowley; Constance M Moore
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-10-29       Impact factor: 8.829

3.  Managing bipolar disorder from urgent situations to maintenance therapy.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

4.  Effect of divalproex on brain morphometry, chemistry, and function in youth at high-risk for bipolar disorder: a pilot study.

Authors:  Kiki Chang; Asya Karchemskiy; Ryan Kelley; Meghan Howe; Amy Garrett; Nancy Adleman; Allan Reiss
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-02       Impact factor: 2.576

5.  N-acetylaspartate normalization in bipolar depression after lamotrigine treatment.

Authors:  Paul E Croarkin; M Albert Thomas; John D Port; Joshua M Baruth; Doo-Sup Choi; Osama A Abulseoud; Mark A Frye
Journal:  Bipolar Disord       Date:  2014-12-12       Impact factor: 6.744

Review 6.  A review of MR spectroscopy studies of pediatric bipolar disorder.

Authors:  D G Kondo; T L Hellem; X-F Shi; Y H Sung; A P Prescot; T S Kim; R S Huber; L N Forrest; P F Renshaw
Journal:  AJNR Am J Neuroradiol       Date:  2014-02-20       Impact factor: 3.825

7.  Neurometabolite effects of response to quetiapine and placebo in adolescents with bipolar depression.

Authors:  Kiki Chang; Melissa Delbello; Wen-Jang Chu; Amy Garrett; Ryan Kelley; Neil Mills; Meghan Howe; Holly Bryan; Cal Adler; Jim Eliassen; Daniel Spielman; Stephen M Strakowski
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-07-31       Impact factor: 2.576

8.  A comparison of affected and unaffected relatives of patients with bipolar disorder using proton magnetic resonance spectroscopy.

Authors:  Tomas Hajek; Denise Bernier; Claire Slaney; Lukas Propper; Matthias Schmidt; Normand Carrey; Glenda MacQueen; Anne Duffy; Martin Alda
Journal:  J Psychiatry Neurosci       Date:  2008-11       Impact factor: 6.186

Review 9.  The neurotrophic and neuroprotective effects of psychotropic agents.

Authors:  Joshua Hunsberger; Daniel R Austin; Ioline D Henter; Guang Chen
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

10.  Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients.

Authors:  Ann E Maloney; Linmarie Sikich
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-10       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.